P3 Health Partners (NASDAQ:PIII) Raised to Hold at Wall Street Zen

P3 Health Partners (NASDAQ:PIII) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a report released on Saturday.

Several other brokerages have also recently weighed in on PIII. TD Cowen restated a “hold” rating and issued a $14.00 price objective (up from $3.00) on shares of P3 Health Partners in a report on Friday, May 22nd. Lake Street Capital reissued a “buy” rating and set a $14.00 price objective (up from $4.00) on shares of P3 Health Partners in a report on Friday, May 15th. UBS Group set a $14.00 price objective on P3 Health Partners in a research report on Friday, May 15th. Finally, Weiss Ratings raised P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 28th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, P3 Health Partners has an average rating of “Hold” and an average price target of $14.00.

P3 Health Partners Stock Performance

Shares of PIII opened at $11.37 on Friday. P3 Health Partners has a 12 month low of $1.52 and a 12 month high of $16.89. The firm has a fifty day simple moving average of $9.48 and a 200 day simple moving average of $5.15. The stock has a market capitalization of $82.32 million, a price-to-earnings ratio of -0.29 and a beta of 1.62.

P3 Health Partners (NASDAQ:PIII) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.85) by $5.17. The business had revenue of $386.39 million during the quarter, compared to analyst estimates of $391.45 million.

Institutional Investors Weigh In On P3 Health Partners

An institutional investor recently bought a new stake in P3 Health Partners stock. Lido Advisors LLC purchased a new stake in P3 Health Partners Inc. (NASDAQ:PIII) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,748 shares of the company’s stock, valued at approximately $33,000. Lido Advisors LLC owned 0.15% of P3 Health Partners as of its most recent filing with the Securities and Exchange Commission. 7.75% of the stock is owned by institutional investors and hedge funds.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.